Based on technology exclusively licensed from the University of Pennsylvania, the company’s proprietary Senza5 platformutilises the antitumor potential of engineered T cells, with pipeline applications in oncology and autoimmune diseases.

Vittoria hopes to advance its lead program, VIPER-101, into the clinic for the treatment of T-cell lymphoma.